New genetic eye disease discovered

Research & Development

Researchers from the National Eye Institute (NEI), part of the National Institutes of Health, have identified a new disease that affects the macula. The new type of macular dystrophy is a cause of central vision loss.

The macula is a small part of the light-sensing retina needed for sharp, central vision. Macular dystrophies cause central visual loss, due to mutations in several genes, including ABCA4, BEST1, PRPH2, and TIMP3.

“We found it surprising that two patients had TIMP3 variants not in the mature protein, but in the short signal sequence the gene uses to ‘cut’ the protein from the cells. We showed these variants prevent cleavage, causing the protein to be stuck in the cell, likely leading to retinal pigment epithelium toxicity,” said Bin Guan, PhD, lead author.

Rob Hufnagel, MD, PhD, senior author and director of the Ophthalmic Genomics Laboratory at NEI, elaborated: “Discovering novel disease mechanisms, even in known genes like TIMP3, may help patients that have been looking for the correct diagnosis, and will hopefully lead to new therapies for them.”

NEI’s Ophthalmic Genomics Laboratory gathers and manages specimens and diagnostic data from patients who have been recruited into multiple studies within the NEI clinical program, to facilitate research of rare eye diseases. This includes Sorsby Fundus Dystrophy, which causes similar symptoms to agerelated macular degeneration (AMD), though it generally affects patients at a younger age.

“Affected individuals had scotomas, or blind spots, and changes in their maculas indicative of disease, but, for now, they have preserved central vision and no choroidal neovascularisation, unlike typical Sorsby Fundus Dystrophy,” said Cathy Cukras, MD, PhD, a Lasker tenuretrack investigator and medical retina specialist who clinically evaluated the patients.

GSK’s RSV vaccine approved by MHRA

GSK has announced that the MHRA has authorised its Arexvy respiratory syncytial virus (RSV) vaccine for active immunisation for the prevention of lower respiratory tract disease (LRTD) caused by RSV in adults over the age of 60.

RNAi treatment for hypertension developed by Alnylam and Roche

Alnylam Pharmaceuticals has announced that it has entered a strategic agreement with Roche for the development and commercialisation of zilebesiran, Alnylam’s investigational RNAi therapeutic for the treatment of hypertension in patients with high cardiovascular risk.

GSK’s novel gonorrhoea vaccine gains Fast Track designation from FDA

GSK has announced that the FDA has granted fast track designation for its investigational vaccine for gonorrhoea, which is currently in an ongoing phase 2 trial assessing the efficacy of the vaccine in healthy adults aged 18 to 50 who are considered at risk of contracting gonorrhoea.

Data from Eli Lilly’s two phase 3 tirzepatide studies shared

Eli Lilly has announced results from its two phase 3 tirzepatide studies in adult patients with obesity or who are overweight with weight-related comorbidities, excluding type 2 diabetes.

Study shows Wegovy by Novo Nordisk reduces cardiovascular risk

Novo Nordisk has shared results from the select cardiovascular outcomes trial, which show that a once-weekly subcutaneous dose of Wegovy (semaglutide 2.4mg) reduced the risk of major adverse cardiovascular events (mace) by 20% in overweight or obese adults over the age of 45 with established cardiovascular disease (CVD) and no prior history of diabetes.

GSK’s RSV vaccine approved by MHRA

RNAi treatment for hypertension developed by Alnylam and Roche

GSK’s novel gonorrhoea vaccine gains Fast Track designation from FDA

Data from Eli Lilly’s two phase 3 tirzepatide studies shared

Study shows Wegovy by Novo Nordisk reduces cardiovascular risk

Pharmafocus

Categories

Social Footprints